Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Microsoft

- PMLiVE

Eli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m

The companies will use Genetic Leap's AI platform to generate oligonucleotide drugs against targets selected by Lilly

- PMLiVE

Acelyrin shares positive phase 3 results for izokibep in hidradenitis suppurativa

Despite the promising readout, the company said it will not be moving forward with the candidate in the inflammatory skin condition

- PMLiVE

Researchers develop AI model to identify breast cancer stages and progression

Up to 50% of ductal carcinoma in situ patients progress to a highly invasive stage of cancer

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Almirall announces NICE recommendation for Ebglyss in atopic dermatitis

The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK

- PMLiVE

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Eli Lilly partners with OpenAI to discover antimicrobials for drug-resistant pathogens

Antimicrobial resistance has been declared by WHO as one of the top ten global public health threats

- PMLiVE

Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

The neurodegenerative condition currently affects nearly ten million people worldwide

- PMLiVE

GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers

There are more than 10,000 deaths due to liver disease each year in the UK

- PMLiVE

Almirall’s Klisyri receives expanded FDA approval to treat actinic keratosis

The precancerous condition is responsible for an estimated 60% of all squamous cell carcinoma cases

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions

- PMLiVE

Sanofi, Formation Bio and OpenAI announce AI collaboration to accelerate drug development

The companies will combine data, software and tuned models to bring new medicines to patients more efficiently

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links